<html xmlns:fo="http://www.w3.org/1999/XSL/Format">

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_didanosine.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:22:41 GMT -->
<head>
<META http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<title>Johns Hopkins POC-IT: Point of Care Information Technology</title>
<meta content="text/html; charset=iso-8859-1" http-equiv="Content-Type">
<link href="../../images/styles.css" type="text/css" rel="stylesheet">
<script type="text/JavaScript" src="../../images/functions.js" language="JavaScript"></script>
</head>
<body>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td>Johns Hopkins POC-IT: Point of Care Information Technology</td><td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td></td><td>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td class="tdVAlignMiddle" align="center" >
                                                            &nbsp;</td>
</tr>
<tr></tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
<tr>
<td  ><span class="mainNav">&nbsp;Print-Friendly Module</span></td>
</tr>
</table>
</td>
</tr>
</table>
<p></p>
<table cellspacing="0" cellpadding="0" border="0" >
<tr>
<td></td><td>
<table >
<tr>
<td><span class="primaryItemTitle"><font size="6">Didanosine</font></span>
<br>
</td><td align="right" valign="top"><a href="javascript:window.print();"></a></td>
</tr>
<tr>
<td colspan="2">
<br>
        Author: <author maxOccurance="1" tag="author" use="required">Paul A. Pham, Pharm.D. and John G. Bartlett, M.D.</author>
<br>
<span class="display_date">06-18-2008</span>
<br>
<div style="background-color:#ccffcc;">
<a name=""></a>
<h2 class="grayLineHeaderBar"></h2>
<ul>
<li>
<B>Available formulation in Zambia: Buffered powder for oral liquid:</B> 100 mg; 167 mg; 250 mg packets. <B>Capsule (unbuffered enteric-coated):</B> 125 mg; 200 mg; 250 mg; 400 mg. <B>Tablet (buffered chewable, dispersible): </B>25 mg; 50 mg; 100 mg; 150 mg; 200 mg. </li>
<li>Avoid co-administration with <A class="headLines" target="_new" href="../antimicrobial_agents/isoniazidfda2.html?contentInstanceId=434165">INH</A> due to potential for <A class="headLines" target="_new" href="../../diagnosis/organ_system/neuropathy__peripheralce31.html?contentInstanceId=432761">peripheral neuropathy</A>. </li>
</ul>Zambia Information Author: Paul A. Pham, Pharm. D. <br>
<br>
</div>
<a name="INDICATIONS"></a>
<h2 class="grayLineHeaderBar">INDICATIONS</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">FDA</span></td>
</tr>
</table>
<hr>
<ul>
<li>Treatment of HIV infection in combination with other antiretrovirals. </li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">NON-FDA APPROVED USES</span></td>
</tr>
</table>
<hr>
<ul>
<li>&nbsp;</li>
</ul>
<a name="FORMS"></a>
<h2 class="grayLineHeaderBar">FORMS</h2>
<TABLE  class="blueOutline" cellspacing="0" cellpadding="2" border="0">
<TR class="blueBarBG">
<TD><B>brand name</B></TD><TD><B>preparation</B></TD><TD><B>manufacturer</B></TD><TD><B>route</B></TD><TD><B>form</B></TD><TD><B>dosage^</B></TD><TD><B>cost*</B></TD>
</TR>
        
<TR>
<TD valign="top">
            <I>Videx</I>
          </TD><TD valign="top">ddI</TD><TD valign="top">Bristol-Myers Squibb</TD><TD>oral</TD><TD>pediatric powder </TD><TD>2000 mg (4oz); 4000 mg (8oz)</TD><TD>$52.81  per 4oz; $115.30  per 8oz</TD>
</TR>
        
<TR>
<TD valign="top">
            <I>Videx EC</I>
          </TD><TD valign="top">didanosine </TD><TD valign="top">Bristol-Myers Squibb&nbsp;</TD><TD>oral</TD><TD>enteric coated caps</TD><TD>125 mg; 200 mg; 250 mg; 400 mg</TD><TD> $4.29; $6.86; $8.73; $13.65 </TD>
</TR>
        
<TR>
<TD valign="top">Didanosine EC (generic)</TD><TD valign="top">didanosine&nbsp;</TD><TD valign="top">Barr Laboratories INC </TD><TD>oral </TD><TD>capsule </TD><TD>200 mg, 250 mg, 400 mg </TD><TD>$6.16; $7.87; $12.27 </TD>
</TR>
      
</TABLE>
<p>*Costs (rounded to the nearest dollar) are based on usual adult dosing per day, 
                are representative of "Average Wholesale Price" (AWP), and are current within the prior three months.</p>
<p>^Dosage is indicated in mg unless otherwise noted.</p>
<a name="USUAL ADULT DOSING"></a>
<h2 class="grayLineHeaderBar">USUAL ADULT DOSING</h2>Pill burden: 1 per day (ddI EC)<br>
<br>
<ul>
<li>Wt &gt;60&nbsp;kg dose: 400 mg PO once-daily.&nbsp;EC cap on an empty stomach (&gt;1 hr before of &gt;2 hrs after meals).</li>
<li>Wt &lt;60&nbsp;kg dose: 250 mg PO once-daily.&nbsp;EC cap on an empty stomach (&gt;1 hr before of &gt;2 hrs after meals).</li>
<li>Total daily dose may also be taken in 2 divided doses if GI tolerance is an issue.</li>
<li>Dose adjustment with <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">tenofovir</A> co-administration: &lt;60kg, 200 mg once-daily; &gt;60kg, 250 mg once-daily (see drug-drug interaction section for additional warnings). </li>
</ul>
<a name="RENAL DOSING"></a>
<h2 class="grayLineHeaderBar">RENAL DOSING</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 50-80</span></td>
</tr>
</table>
<hr>Wt &gt;60 kg dose: 400 mg PO once-daily (tabs) or 500 mg PO once-daily (powder). Wt &lt;60 kg dose: 250 mg PO once-daily (tabs) or 334 mg PO once-daily (powder). <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 10-50</span></td>
</tr>
</table>
<hr>50% of usual dose once-daily. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF &lt;10 ML/MIN</span></td>
</tr>
</table>
<hr>25% of usual dose once-daily. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMODIALYSIS</span></td>
</tr>
</table>
<hr>25% of usual dose once-daily, on days of dialysis give post dialysis. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN PERITONEAL DIALYSIS</span></td>
</tr>
</table>
<hr>25% of usual dose (little effect on removal with PD) [<A class="headLines" target="_new" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=8941026&amp;dopt=abstract">Clin Pharmacol Ther. 1996;60(5):535</A>]. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMOFILTRATION</span></td>
</tr>
</table>
<hr>No data. <br>
<br>
<a name="ADVERSE DRUG REACTIONS"></a>
<h2 class="grayLineHeaderBar">ADVERSE DRUG REACTIONS</h2>Fewer GI side effects with EC formulation than with buffered, powder,&nbsp;or pediatric solution formulations <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">COMMON</span></td>
</tr>
</table>
<hr>
<ul>
<li>Time-and dose-dependent <A class="headLines" target="_new" href="../../diagnosis/organ_system/neuropathy__peripheralce31.html?contentInstanceId=432761">peripheral neuropathy</A> (5-12% of pts after 2-6 mos of therapy). Relative risk of neuropathy is 135% higher when combined with hydroxyurea (HU), 250% higher with <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A>, and 680% higher with <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A> + HU.&nbsp;Irreversible and debilitating neuropathy with continued use despite early Ssxs.</li>
<li>GI intolerance (<A class="headLines" target="_new" href="../../diagnosis/organ_system/nausea_vomiting1649.html?contentInstanceId=432759">nausea, vomiting</A>, and <A class="headLines" target="_new" href="../../diagnosis/organ_system/diarrhea8e47.html?contentInstanceId=432753">diarrhea</A> ) esp. with buffered tablets. </li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">OCCASIONAL</span></td>
</tr>
</table>
<hr>
<ul>
<li>Dose dependent <A class="headLines" target="_new" href="../../diagnosis/organ_system/pancreatitis91f4.html?contentInstanceId=432764">pancreatitis</A>&nbsp;(in 1-9% of pts, with 6% cases fatal). Risk factors associated with ddI-induced <A class="headLines" target="_new" href="../../diagnosis/organ_system/pancreatitis91f4.html?contentInstanceId=432764">pancreatitis</A>: alcohol use, renal failure, obesity, and concurrent use of <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A>, HU, allopurinol, or pentamidine. </li>
<li>Reversible transaminase elevation. </li>
<li>
<A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/lipodystrophy94a9.html?contentInstanceId=432804">Lipoatrophy</A>. Best characterized with ddI+<A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A>; may occur when ddI used without <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A>.</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">RARE</span></td>
</tr>
</table>
<hr>
<ul>
<li>
<A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/lactic_acidosis9dee.html?contentInstanceId=432782">Lactic acidosis</A> and severe hepatomegaly with steatosis (can be fatal in severe cases).</li>
<li>Rash and optic neuritis.</li>
</ul>
<a name="DRUG INTERACTIONS"></a>
<h2 class="grayLineHeaderBar">DRUG INTERACTIONS</h2>ddI does not interact with CYP3A4. Majority of drug interactions with buffered formulation, as buffer can decrease the absorption of some coadministered drugs. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">Drug-to-Drug Interactions</span></td>
</tr>
</table>
<hr>
<a name="Drug-to-Drug Interaction"></a>
<h2 class="grayLineHeaderBar">Drug-to-Drug Interaction</h2>
<TABLE class="blueOutline" CELLPADDING="2" CELLSPACING="0"  BORDER="0">
<tr class="blueBarBG">
<td>Drug</td><td>Effect of Interaction</td><td>Recommendations/Comments</td>
</tr>
<TR>
<TD valign="top"><B></B></TD><TD valign="top"></TD><TD valign="top"></TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A>
          </B></TD><TD valign="top">ATV AUC: decreased by 87%; Cmin: decreased by 84% with ddI (buffered). ddI EC:ddI AUC increased by 26% and ATV AUC decreased by 11%.</TD><TD valign="top">Administer ddI (pediatric solution) on empty stomach 2 hrs before or 1 hr after food or <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A>. Use ddI EC if possible, since interaction unlikely to be significant, especially when <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> is boosted with <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> (<A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> 300 mg + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>100 mg).</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A>
          </B></TD><TD valign="top">Increased risk of <A class="headLines" target="_new" href="../../diagnosis/organ_system/neuropathy__peripheralce31.html?contentInstanceId=432761">peripheral neuropathy</A>, <A class="headLines" target="_new" href="../../diagnosis/organ_system/pancreatitis91f4.html?contentInstanceId=432764">pancreatitis</A>, and <A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/lactic_acidosis9dee.html?contentInstanceId=432782">lactic acidosis</A>.</TD><TD valign="top">Do not co-administer.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="../antimicrobial_agents/dapsone00f4.html?contentInstanceId=441413">Dapsone</A>
          </B></TD><TD valign="top"><A class="headLines" target="_new" href="../antimicrobial_agents/dapsone00f4.html?contentInstanceId=441413">Dapsone</A>: no change. Early single dose PK study found a decrease in <A class="headLines" target="_new" href="../antimicrobial_agents/dapsone00f4.html?contentInstanceId=441413">dapsone</A> serum levels, however multiple dose studies did not find a significant change in <A class="headLines" target="_new" href="../antimicrobial_agents/dapsone00f4.html?contentInstanceId=441413">dapsone</A> serum levels with ddI (buffer) <BR>co-administration.</TD><TD valign="top">No significant interaction. Use standard dose. ddI EC not studied but interaction unlikely.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>
          </B></TD><TD valign="top"><A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> AUC decreased by 32%</TD><TD valign="top">Applies to ddI buffered formulation only. Separate administration time by at least 2 hrs or use ddI EC formulation (not studied but interaction unlikely).</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>
          </B></TD><TD valign="top"><A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>: no change (with ddI EC). <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> AUC decreased by 84% (with ddI buffered).</TD><TD valign="top">No significant interaction with ddI EC (use standard dose). Administer <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> 1 hr before or after ddI (pediatric solution).</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="../antimicrobial_agents/isoniazidfda2.html?contentInstanceId=434165">Isoniazid</A>
          </B></TD><TD valign="top">May increase risk of <A class="headLines" target="_new" href="../../diagnosis/organ_system/neuropathy__peripheralce31.html?contentInstanceId=432761">peripheral neuropathy</A>.</TD><TD valign="top">Give <A class="headLines" target="_new" href="../antimicrobial_agents/isoniazidfda2.html?contentInstanceId=434165">INH</A> with pyridoxine to decrease the risk of neuropathy. Monitor for <A class="headLines" target="_new" href="../../diagnosis/organ_system/neuropathy__peripheralce31.html?contentInstanceId=432761">peripheral neuropathy</A>. Irreversible neuropathy with continued use. Avoid long term co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="../antimicrobial_agents/metronidazoleb50a.html?contentInstanceId=434168">Metronidazole</A>
          </B></TD><TD valign="top">May increase risk of <A class="headLines" target="_new" href="../../diagnosis/organ_system/neuropathy__peripheralce31.html?contentInstanceId=432761">peripheral neuropathy</A> (rare).</TD><TD valign="top">Monitor for <A class="headLines" target="_new" href="../../diagnosis/organ_system/neuropathy__peripheralce31.html?contentInstanceId=432761">peripheral neuropathy</A>. Irreversible neuropathy with continued use. Avoid long term co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>
          </B></TD><TD valign="top">ddI AUC: decreased by 15%.</TD><TD valign="top">Applies to pediatric solution. Clinical significance unknown. Separate ddI and <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> administration by at least 2 hrs. No data with ddI EC but interaction unlikely. </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>
          </B></TD><TD valign="top">ddI EC AUC: increased by 48% (fasted); ddI EC AUC: increased by 60% (fed) <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>: no change. Suboptimal response in 91% of pts with ddI/<A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>.</TD><TD valign="top">Dose adjust ddI to 250 mg PO once-daily (<U>&gt;</U>60 kg) with <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A> co-administration. Combination with unadjusted ddI dose may lead to CD4 decline. Do not use ddI/<A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> as sole triple nucleoside regimen or NNRTI/ddI/<A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A> due to high rates of virologic failure.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="../antimicrobial_agents/tetracycline995d.html?contentInstanceId=434163">Tetracyclines</A>
          </B></TD><TD valign="top">Not studied. May decrease tetracyclines serum levels due to chelation by the divalent cation of the ddI buffer.</TD><TD valign="top">Applies to pediatric solution. Consider ddI EC or administer ddI suspension 6 hrs prior to or 2 hrs after <A class="headLines" target="_new" href="../antimicrobial_agents/tetracycline995d.html?contentInstanceId=434163">tetracycline</A> administration. No data with ddI EC but interaction unlikely.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="../antimicrobial_agents/valganciclovir9672.html?contentInstanceId=441408">Valganciclovir</A>
          </B></TD><TD valign="top">Not studied. ddI AUC may be significantly increased.</TD><TD valign="top">Clinical significance unknown. Monitor for ddI toxicity (neuropathy, <A class="headLines" target="_new" href="../../diagnosis/organ_system/pancreatitis91f4.html?contentInstanceId=432764">pancreatitis</A>, and <A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/lactic_acidosis9dee.html?contentInstanceId=432782">lactic acidosis</A>).</TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="../antimicrobial_agents/ganciclovir89d6.html?contentInstanceId=437816">Ganciclovir</A> (IV and PO)</B></TD><TD valign="top">Co-administration with ddI (buffered formulation) resulted in a 111% increased in ddI AUC. <A class="headLines" target="_new" href="../antimicrobial_agents/ganciclovir89d6.html?contentInstanceId=437816">Ganciclovir</A> AUC decreased by 21%. </TD><TD valign="top">Clinical significance unknown, but monitor closely for ddI toxicity. No data with ddI EC.</TD>
</TR>
<TR>
<TD valign="top"><B>Allopurinol</B></TD><TD valign="top">May significantly increase ddI serum levels. ddI (buffered formulation) AUC increased by 120%.</TD><TD valign="top"> PK studies conducted with ddI (buffered), but interaction also applies to ddI EC.. Clinical significance unknown. Do not co-administer.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Cidofovir
          </B></TD><TD valign="top">3 mg/kg IV (with probenecid) on days 1 and 8 ddI AUC: increased by 60%. Possible inhibition of renal tubular secretion by probenecid and/or cidofovir.</TD><TD valign="top">Applies to pediatric solution). Monitor for ddI toxicity, but unlikely to be significant since cidofovir is only administered every other wk with probenecid.</TD>
</TR>
<TR>
<TD valign="top"><B>Cisplatin</B></TD><TD valign="top">May increase risk of <A class="headLines" target="_new" href="../../diagnosis/organ_system/neuropathy__peripheralce31.html?contentInstanceId=432761">peripheral neuropathy</A>.</TD><TD valign="top">Monitor for <A class="headLines" target="_new" href="../../diagnosis/organ_system/neuropathy__peripheralce31.html?contentInstanceId=432761">peripheral neuropathy</A>. Irreversible neuropathy with continued use. Avoid long term co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B>Disulfiram</B></TD><TD valign="top">May increase risk of <A class="headLines" target="_new" href="../../diagnosis/organ_system/neuropathy__peripheralce31.html?contentInstanceId=432761">peripheral neuropathy</A>.</TD><TD valign="top">Monitor for <A class="headLines" target="_new" href="../../diagnosis/organ_system/neuropathy__peripheralce31.html?contentInstanceId=432761">peripheral neuropathy</A>. Irreversible neuropathy with continued use. Avoid long term co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B>Fluoroquinolone (<A class="headLines" target="_new" href="../antimicrobial_agents/ciprofloxacin0f26.html?contentInstanceId=434153">Ciprofloxacin</A>)</B></TD><TD valign="top"><A class="headLines" target="_new" href="../antimicrobial_agents/ciprofloxacin0f26.html?contentInstanceId=434153">Ciprofloxacin</A>: AUC decreased by 26% with ddI (buffered). ddI: not affected.<BR>
<A class="headLines" target="_new" href="../antimicrobial_agents/ciprofloxacin0f26.html?contentInstanceId=434153">Ciprofloxacin</A> not affected by ddI EC.</TD><TD valign="top">Consider ddI EC (<A class="headLines" target="_new" href="../antimicrobial_agents/ciprofloxacin0f26.html?contentInstanceId=434153">ciprofloxacin</A> not affected) or administer ddI suspension 6 hrs prior to or 2 hrs after <A class="headLines" target="_new" href="../antimicrobial_agents/ciprofloxacin0f26.html?contentInstanceId=434153">ciprofloxacin</A> administration. Study performed with <A class="headLines" target="_new" href="../antimicrobial_agents/ciprofloxacin0f26.html?contentInstanceId=434153">ciprofloxacin</A>, but all other fluoroquinolones may also be significantly affected by buffered ddI.</TD>
</TR>
<TR>
<TD valign="top"><B>Food </B></TD><TD valign="top">ddI AUC decreased by 18-27% w/ EC formulation; AUC decreased by 47% with buffered formulation.</TD><TD valign="top">Administer all forms of ddI on empty stomach (1 hr before or 2 hrs after meals).</TD>
</TR>
<TR>
<TD valign="top"><B>Gold compounds</B></TD><TD valign="top">May increase risk of <A class="headLines" target="_new" href="../../diagnosis/organ_system/neuropathy__peripheralce31.html?contentInstanceId=432761">peripheral neuropathy</A>.</TD><TD valign="top">Monitor for <A class="headLines" target="_new" href="../../diagnosis/organ_system/neuropathy__peripheralce31.html?contentInstanceId=432761">peripheral neuropathy</A>. Irreversible neuropathy with continued use. Avoid long term co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B>Hydralazine</B></TD><TD valign="top">May increase risk of <A class="headLines" target="_new" href="../../diagnosis/organ_system/neuropathy__peripheralce31.html?contentInstanceId=432761">peripheral neuropathy</A>.</TD><TD valign="top">Monitor for <A class="headLines" target="_new" href="../../diagnosis/organ_system/neuropathy__peripheralce31.html?contentInstanceId=432761">peripheral neuropathy</A>. Irreversible neuropathy with continued use. Avoid long term co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Hydroxyurea
          </B></TD><TD valign="top">Increased risk of <A class="headLines" target="_new" href="../../diagnosis/organ_system/pancreatitis91f4.html?contentInstanceId=432764">pancreatitis</A> and <A class="headLines" target="_new" href="../../diagnosis/organ_system/neuropathy__peripheralce31.html?contentInstanceId=432761">peripheral neuropathy</A>.</TD><TD valign="top">Do not co-administer.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Itraconazole
          </B></TD><TD valign="top">Itraconazole Cmax: undetectable</TD><TD valign="top">Applies to ddI (pediatric solution). Administer itraconazole caps at least 2 hrs after ddI suspension. No interaction with ddI EC (preferred).</TD>
</TR>
<TR>
<TD valign="top"><B>
            Ketoconazole
          </B></TD><TD valign="top">Ketoconazole: No change (with ddI EC). Decreased in ketoconazole absorption (with ddI buffered).</TD><TD valign="top">No significant interaction with ddI EC (use standard dose). Administer itraconazole caps at least 2 hrs after ddI suspension.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Methadone
          </B></TD><TD valign="top">ddI (buffered) AUC decreased by 60%. Methadone serum levels not affected. No interaction with ddI EC formulation.</TD><TD valign="top">Clinical significance unknown. Use ddI EC with methadone.</TD>
</TR>
<TR>
<TD valign="top"><B>Pentamidine (IV)</B></TD><TD valign="top">May increase risk of <A class="headLines" target="_new" href="../../diagnosis/organ_system/pancreatitis91f4.html?contentInstanceId=432764">pancreatitis</A>.</TD><TD valign="top">Caution when administering to pts with history of alcoholism. Avoid in pts currently abusing alcohol.</TD>
</TR>
<TR>
<TD valign="top"><B>Pyridoxine (Vitamin B6) high-dose</B></TD><TD valign="top">May increase risk of <A class="headLines" target="_new" href="../../diagnosis/organ_system/neuropathy__peripheralce31.html?contentInstanceId=432761">peripheral neuropathy</A>.</TD><TD valign="top">Monitor for <A class="headLines" target="_new" href="../../diagnosis/organ_system/neuropathy__peripheralce31.html?contentInstanceId=432761">peripheral neuropathy</A>. Irreversible neuropathy with continued use. Avoid long term co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Ribavirin
          </B></TD><TD valign="top">Increased risk of mitochondrial toxicity FDA case reports: 21 out of 27 cases associated with <A class="headLines" target="_new" href="../../diagnosis/organ_system/pancreatitis91f4.html?contentInstanceId=432764">pancreatitis</A>, 5 deaths due to <A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/lactic_acidosis9dee.html?contentInstanceId=432782">lactic acidosis</A> (all 5 taking ddI + ribavirin).</TD><TD valign="top">Contraindicated. Do not co-administer. Use an alternative NRTI.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Thalidomide
          </B></TD><TD valign="top">May increase risk of <A class="headLines" target="_new" href="../../diagnosis/organ_system/neuropathy__peripheralce31.html?contentInstanceId=432761">peripheral neuropathy</A>.</TD><TD valign="top">Monitor for <A class="headLines" target="_new" href="../../diagnosis/organ_system/neuropathy__peripheralce31.html?contentInstanceId=432761">peripheral neuropathy</A>. Irreversible neuropathy with continued use. Avoid long term co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B>Vincristine</B></TD><TD valign="top">May increase risk of <A class="headLines" target="_new" href="../../diagnosis/organ_system/neuropathy__peripheralce31.html?contentInstanceId=432761">peripheral neuropathy</A>.</TD><TD valign="top">Monitor for <A class="headLines" target="_new" href="../../diagnosis/organ_system/neuropathy__peripheralce31.html?contentInstanceId=432761">peripheral neuropathy</A>. Irreversible neuropathy with continued use. Avoid long term co-administration.</TD>
</TR>
</TABLE>
<a name="RESISTANCE"></a>
<h2 class="grayLineHeaderBar">RESISTANCE</h2>
<ul>
<li>K65R: Selected by ddI, resulting in intermediate resistance to ddI, <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>, <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>, <A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A>, and low-level resistance to <A class="headLines" target="_new" href="abacavirc37e.html?contentInstanceId=432939">ABC</A> and possibly <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A>. When present with 184V, susceptibility to <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A> improves, susceptibility to <A class="headLines" target="_new" href="abacavirc37e.html?contentInstanceId=432939">ABC</A> and ddI further decreased. </li>
<li>L74V: Selected by ddI, resulting in intermediate resistance to ddI and low-level resistance to <A class="headLines" target="_new" href="abacavirc37e.html?contentInstanceId=432939">ABC</A>. When present with 184V, causes further loss of susceptibility to <A class="headLines" target="_new" href="abacavirc37e.html?contentInstanceId=432939">ABC</A> and ddI. May increase susceptibility to <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>, <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A>, and <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>. </li>
<li>Q151M complex: High-level resistance. </li>
<li>T69S insertion: High-level resistance. </li>
<li>TAMs (41L, 210W, 215Y/F,219Q/E, 44D, 67N, 70R, 118I): Intermediate- or high-level resistance with 3 or more TAMs, especially with 41L/210W/215Y pathway.</li>
<li>184V: slight decrease in sensitivity to ddI but not clinically significant. </li>
</ul>
<a name="PHARMACOLOGY"></a>
<h2 class="grayLineHeaderBar">PHARMACOLOGY</h2>
<a name="N10BBE"></a>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">MECHANISM</span></td>
</tr>
</table>
<hr>Metabolized intracellularly to ddATP (active metabolite), which competitively inhibits HIV DNA polymerase.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PHARMACOKINETIC PARAMETERS</span></td>
</tr>
</table>
<hr>
<ul>
<li>Absorption: 
                30% absorption with powder</li>
<li>Metabolism and Excretion: 
                50% excreted unchanged in the urine via glomerular filtration and tubular secretion.</li>
<li>Protein Binding: 
                &lt;5%</li>
<li>Cmax, Cmin, and AUC: 
                Cmax = 1.6 mcg/mL after a single dose of 375 mg</li>
<li>T1/2: 
                Serum:1.6 hrs; Intracellular: 25-40 hrs.</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR DECREASED HEPATIC FUNCTION</span></td>
</tr>
</table>
<hr>No data: Usual dose likely. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PREGNANCY RISK</span></td>
</tr>
</table>
<hr>Category B: human studies demonstrated 35% (range 23-59%) placental passage. In 8 pts studied, no toxicities were observed in mothers, infants. Due to the small number of pts no firm conclusion can be made. In a phase I study (PACTG 249) ddI was well tolerated by women and fetus when started at wk 26-36. Pregnant pts may be at increase risk of <A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/lactic_acidosis9dee.html?contentInstanceId=432782">lactic acidosis</A> (FDA warns against its use in combination with <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A> in pregnant pts). <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">BREAST FEEDING COMPATIBILITY</span></td>
</tr>
</table>
<hr>Unknown breast milk excretion. Breast feeding not recommended in the U.S. in order to avoid post-natal transmission of HIV to the child, who may not yet be infected.<a name="COMMENTS"></a>
<h2 class="grayLineHeaderBar">COMMENTS</h2>
<ul>
<li>Pros: good clinical track record; once daily administration; excellent results in uncontrolled trials when combined with <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> or <A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A> and 3rd agent</li>
<li>Cons: GI intolerance with pediatric solution; need to be taken on an empty stomach; <A class="headLines" target="_new" href="../../diagnosis/organ_system/pancreatitis91f4.html?contentInstanceId=432764">pancreatitis</A>, neuropathy, and mitochondrial toxicity; relative lack of controlled data in HAART era for ddI + <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> or ddI + <A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A> compared to other dual-NRTI backbones; lack of coformulation; cross-resistance with <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>, <A class="headLines" target="_new" href="abacavirc37e.html?contentInstanceId=432939">ABC</A>; not preferred as a first line NRTI in current DHHS treatment guidelines.&nbsp;May increase risk of MI, especially in patients with with cardiovascular risk factors.</li>
</ul>
<a name="N10C26"></a><a name="References"></a>
<h2 class="grayLineHeaderBar">References</h2>
<ol>
<li>D:A:D Study Group, Sabin CA, Worm SW, Weber R, et al. ;
		Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. ;        
		Lancet ;
		2008 ; Vol. 
		371 ; pp. 
		1417-26 ;
		<br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=18387667&amp;dopt=abstract" target="_new">18387667 </a>
<br>
<b>Comments:</b>A retrospective review of the D:A:D observational cohort for cardiovascular disease risks-associated with NRTI use included 33347 pts (157,912 pt yrs of follow-up). ddI-containing regimens. was associated with an increased risk of MI (RR 1.49 (95% CI 1.14-1.95). There was also an increased risk associated with ABC treatment, but not d4T or AZT. Apparent pathophysilogic mechanism of this finding has not been identified. <br>
<br>
</li>
<li>Molina JM, Journot V, Furco A, et al.;
		Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial).;        
		Antivir Ther;
		2007; Vol. 
		12; pp. 
		417-22;
		<br>ISSN:
	        	1359-6535;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=17591032&amp;dopt=abstract" target="_new">17591032</a>
<br>
<b>Comments:</b>An observational study involving 40 ART-naive HIV-1-infected patients treated with once-daily <A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A>/ddI/<A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> demonstrated good long term virologic efficacy. After 5 years, 73% and 68% of patients had plasma HIV RNA levels &lt; 400 and &lt; 50 copies/ml, respectively (ITT analysis). <br>
<br>
</li>
<li>Saag MS, Cahn P, Raffi F, et al.;
		Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial.;        
		JAMA;
		2004; Vol. 
		292; pp. 
		180-9;
		<br>ISSN:
	        	1538-3598;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=15249567&amp;dopt=abstract" target="_new">15249567</a>
<br>
<b>Comments:</b><A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A> 301 study: 48 week double-blind study that compared once-daily&nbsp;<A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A> or twice-daily <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A>, both given in combination with ddI and <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>. 571-naive pts with mean baseline CD4 of 318 (range 5-1317) and med. baseline VL of 4.9 log (range 2.6-7.0) randomized to receive <A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A>&nbsp;once-daily or <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A> twice-daily, both in combination with ddI and <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>&nbsp;once-daily. Probability of persistent virological response (VL &lt; 50) through wk 60 was 76% for the <A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A> group vs 54% for the <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A> group (p&lt;.001). <br>
<br>
</li>
<li>Robbins GK, De Gruttola V, Shafer RW, et al.;
		Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.;        
		N Engl J Med;
		2003; Vol. 
		349; pp. 
		2293-303;
		<br>ISSN:
	        	1533-4406;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=14668455&amp;dopt=abstract" target="_new">14668455</a>
<br>
<b>Comments:</b>ACTG 384: 620 pts randomized to compare sequential 3-drug regimens in four groups: <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> combined with <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> or <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A>/ddI OR <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A> plus <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> or <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A>/ddI. <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> outperformed <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A> in all arms. With a median of 2.3 yrs of follow-up, <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> combined with <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> had virologic failure in 14% and 23% of pts with the 1st and 2nd regimen, respectively. There was a higher rate of virologic failure in the <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>/<A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A>/ddI arm, with 31% and 58% of pts with the 1st and 2nd regimen, respectively. <A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/lipodystrophy94a9.html?contentInstanceId=432804">Lipoatrophy</A> also occurred more rapidly in the ddI/<A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A> arm. Consistent with the DHHS guidelines, the authors recommend <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>/<A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> as a preferred initial regimen.<br>
<br>
</li>
<li>Jemsek J, Hutcherson P, Harper E.;
		Poor virologic response and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of ddI, 3TC, and TDF. ;        
		<A class="headLines" target="_new" href="http://www.retroconference.org/2004/cd/Abstract/51.htm">11th CROI, San Francisco, California. 2004. Abstract 51</A>. ;
		<br>
<b>Comments:</b>The triple-NRTI regimen of ddI + <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A> + <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> was associated with an unusually high rate of virologic failure (91%) and NRTI resistance in this small trial. <br>
<br>
</li>
<li>Molina J, Marcelin AG, Marcelin J et al.;
		Didanosine in treatment-experienced HIV-infected patients: results from a randomised double-blind study (A1454-176 Jaguar). ;        
		43rd ICAAC, Chicago, Illinois. 2003. Abstract H-447.;
		<br>
<b>Comments:</b>ddI intensification after virologic failure produced a median decrease in VL of 0.5 log c/mL at wk 4. The decrease in VL correlated with the number of TAMs, with no significant response with &gt;3 TAMs. L74V also predicted no response.<br>
<br>
</li>
</ol>
<a name="REFERENCED WITHIN THIS GUIDE"></a>
<h2 class="grayLineHeaderBar">REFERENCED WITHIN THIS GUIDE</h2>
<ul>
<li>
<A class="headLines" target="_new" href="../antimicrobial_agents/doxycycline3770.html?contentInstanceId=432941&amp;siteId=429188">Doxycycline</A>
</li>
<li>
<A class="headLines" target="_new" href="../../guidelines/zambia_hiv_national_guidelines/initial_regimen_for_arv_therapy3770.html?contentInstanceId=432941&amp;siteId=429188">Initial Regimen for ARV Therapy</A>
</li>
<li>
<A class="headLines" target="_new" href="../../guidelines/zambia_hiv_national_guidelines/nutrition_care_and_support3770.html?contentInstanceId=432941&amp;siteId=429188">Nutrition Care and Support</A>
</li>
<li>
<A class="headLines" target="_new" href="../../diagnosis/organ_system/pancreatitis3770.html?contentInstanceId=432941&amp;siteId=429188">Pancreatitis</A>
</li>
<li>
<A class="headLines" target="_new" href="../../management/antiretroviral_therapy/pregnancy_and_perinatal_transmission__zambia_specific_3770.html?contentInstanceId=432941&amp;siteId=429188">Pregnancy and perinatal transmission (Zambia specific)</A>
</li>
<li>
<A class="headLines" target="_new" href="stavudine3770.html?contentInstanceId=432941&amp;siteId=429188">Stavudine</A>
</li>
<li>
<A class="headLines" target="_new" href="../../management/antiretroviral_therapy/toxicity___side_effects__switching_therapy__zambia_spec3770.html?contentInstanceId=432941&amp;siteId=429188">Toxicity &amp; side effects: switching therapy (Zambia specific)</A>
</li>
<li>
<A class="headLines" target="_new" href="../antimicrobial_agents/valganciclovir3770.html?contentInstanceId=432941&amp;siteId=429188">Valganciclovir</A>
</li>
</ul>
<br>
</td>
</tr>
</table>
</td><td></td>
</tr>
</table>
<p></p>
<table cellpadding="0" cellspacing="0" border="0" >
<tr>
<td bgcolor="#003366"></td><td class="bottomNav" bgcolor="#003366" >
<center>
<span class="copyrightFullModule">Copyright 2000-2008 Johns Hopkins University.  All rights reserved.</span>
</center>
</td>
</tr>
</table>
</body>

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_didanosine.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:22:41 GMT -->
</html>
